Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announced that its clinical facility in Mexico City has started recruiting patients for Group Two of its ongoing human clinical study of its next-generation accommodating intraocular lens (the “Ocumetics Lens”). This milestone follows the successful completion of Group One surgeries, which focused solely on safety, and marks a critical step in advancing the lens toward potential commercialization.
The Group Two study will evaluate the safety, distance, and near vision performance of the Ocumetics Lens. Unlike Group One, which was primarily a safety trial, Group Two is designed to assess the functional outcomes of the lens, providing valuable data on its efficacy in restoring a full range of vision. The study will also incorporate the latest-generation Ocumetics Lens, implanted using an enhanced delivery system, reflecting ongoing technological refinements.
Patient recruitment is underway at the Mexico City facility, which previously conducted the Group One surgeries in Fall 2025. The company aims to complete recruitment soon and schedule surgeries for Fall 2026. “We are extremely excited to begin the process of moving into our larger Group Two study,” said Dean Burns, President and CEO of Ocumetics. “Commencement of this study represents another important milestone in the continued clinical development of the Ocumetics Lens.”
The initiation of Group Two coincides with the 12-month follow-up visits for Group One patients, which will provide longer-term clinical data on safety and performance. “We are particularly excited to reach the 12-month milestone for our Group One patients, which will provide an important body of longer-term clinical data as we continue to advance the Ocumetics Lens,” Burns added. The Group One outcomes met and exceeded the company’s expectations regarding safety, performance, and handling, contributing to the decision to proceed with the next phase.
The Ocumetics Lens is designed to be implanted within the natural lens compartment of the eye, potentially eliminating the need for glasses or contact lenses. It utilizes the eye’s natural muscle activity to shift focus between distances, offering clear vision without perceptible time lag. This technology aims to address presbyopia, the age-related loss of near vision, which affects millions worldwide. By providing a dynamic solution that mimics natural accommodation, the Ocumetics Lens could offer a transformative alternative to existing intraocular lenses, which typically correct vision at only one distance.
The progress of the clinical study is closely watched by the ophthalmic industry, as a successful outcome could position Ocumetics as a leader in accommodating lens technology. The company’s commitment to rigorous clinical evaluation and iterative design enhancements underscores its dedication to patient safety and optimal visual outcomes. As Group Two progresses, the data generated will be crucial in determining the lens’s effectiveness and potential regulatory approvals.
Ocumetics Technology Corp. is a Canadian research and product development company focused on advanced vision correction solutions. With its innovative approach and ongoing clinical trials, the company aims to transform the field of ophthalmology and improve the quality of life for patients seeking a broader range of vision.
